A newcastle disease virus (NDV) expressing a membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Sun, W.
    • Other Affiliation: Icahn School of Medicine at Mount Sinai
  • McCroskery, S.
    • Other Affiliation: Icahn School of Medicine at Mount Sinai
  • Liu, W.-C.
    • Other Affiliation: Icahn School of Medicine at Mount Sinai
  • Leist, S.R.
    • Gillings School of Global Public Health, Department of Epidemiology
  • Liu, Y.
    • Other Affiliation: Icahn School of Medicine at Mount Sinai
  • Albrecht, R.A.
    • Other Affiliation: Icahn School of Medicine at Mount Sinai
  • Slamanig, S.
    • Other Affiliation: Icahn School of Medicine at Mount Sinai
  • Oliva, J.
    • Other Affiliation: Icahn School of Medicine at Mount Sinai
  • Amanat, F.
    • Other Affiliation: Icahn School of Medicine at Mount Sinai
  • Schäfer, A.
    • Gillings School of Global Public Health, Department of Epidemiology
  • Dinnon, III, K.H.
    • School of Medicine, Department of Microbiology and Immunology
  • Innis, B.L.
    • Other Affiliation: PATH
  • García-Sastre, A.
    • Other Affiliation: Icahn School of Medicine at Mount Sinai
  • Krammer, F.
    • Other Affiliation: Icahn School of Medicine at Mount Sinai
  • Baric, R.S.
    • Gillings School of Global Public Health, Department of Epidemiology
  • Palese, P.
    • Other Affiliation: Icahn School of Medicine at Mount Sinai
Abstract
  • A successful severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine must not only be safe and protective, but must also meet the demand on a global scale at a low cost. Using the current influenza virus vaccine production capacity to manufacture an egg-based inactivated Newcastle disease virus (NDV)/SARS-CoV-2 vaccine would meet that challenge. Here, we report pre-clinical evaluations of an inactivated NDV chimera stably expressing the membrane-anchored form of the spike (NDV-S) as a potent coronavirus disease 2019 (COVID-19) vaccine in mice and hamsters. The inactivated NDV-S vaccine was immunogenic, inducing strong binding and/or neutralizing antibodies in both animal models. More importantly, the inactivated NDV-S vaccine protected animals from SARS-CoV-2 infections. In the presence of an adjuvant, antigen-sparing could be achieved, which would further reduce the cost while maintaining the protective efficacy of the vaccine.
Date of publication
Keyword
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
License
  • Attribution 3.0 United States
Journal title
  • Vaccines
Journal volume
  • 8
Journal issue
  • 4
Page start
  • 1
Page end
  • 14
Language
  • English
Version
  • Publisher
ISSN
  • 2076-393X
Publisher
  • MDPI AG

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details vaccines-08-00771.pdf 2021-01-04 Public Download